Details of the Drug

General Information of Drug (ID: DM1V5ZS)

Drug Name
Felbamate
Synonyms
Felbamato; Felbamatum; Felbamyl; Felbatol; Taloxa; Essex brand of felbamate; Felbamato [Spanish]; Felbamatum [Latin]; Schering brand of felbamate; F 0778; W 554; Wallace brand 1 of felbamate; Wallace brand 2 of felbamate; ADD-03055; Carbamic acid 2-phenyltrimethylene ester; Felbamate [USAN:INN]; Felbatol (TN); Schering-Plough brand of felbamate; W-554; Carbamic acid, 2-phenyltrimethylene ester; Felbamate (USAN/INN); (3-carbamoyloxy-2-phenyl-propyl) carbamate; (3-carbamoyloxy-2-phenylpropyl) carbamate; 1,3-Propanediol, 2-phenyl-, dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; 2-Phenylpropane-1,3-diyl dicarbamate
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1], [2]
Therapeutic Class
Antiepileptic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 238.24
Topological Polar Surface Area (xlogp) 0.6
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption
The absorption of drug is more than 91% [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [4]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [5]
Elimination
45% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 - 23 hours [6]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 251.84135 micromolar/kg/day [7]
Vd
The volume of distribution (Vd) of drug is 0.756 L/kg [8]
Water Solubility
The ability of drug to dissolve in water is measured as 0.7 mg/mL [4]
Chemical Identifiers
Formula
C11H14N2O4
IUPAC Name
(3-carbamoyloxy-2-phenylpropyl) carbamate
Canonical SMILES
C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
InChI
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
InChIKey
WKGXYQFOCVYPAC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3331
ChEBI ID
CHEBI:4995
CAS Number
25451-15-4
DrugBank ID
DB00949
TTD ID
D05KON
INTEDE ID
DR0684
ACDINA ID
D00266

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [9], [10], [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Felbamate
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Phenobarbital DMXZOCG Moderate Decreased metabolism of Felbamate caused by Phenobarbital mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Coadministration of a Drug Treating the Disease Different from Felbamate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Felbamate and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [43]
Midostaurin DMI6E0R Moderate Increased metabolism of Felbamate caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [44]
Arn-509 DMT81LZ Moderate Increased metabolism of Felbamate caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [45]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Felbamate caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [46]
Oliceridine DM6MDCF Moderate Increased metabolism of Felbamate caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [47]
Ivabradine DM0L594 Moderate Increased metabolism of Felbamate caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [48]
Dronedarone DMA8FS5 Moderate Increased metabolism of Felbamate caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [49]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Felbamate and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [50]
Cilostazol DMZMSCT Moderate Decreased metabolism of Felbamate caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [51]
Telithromycin DMZ4P3A Moderate Increased metabolism of Felbamate caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [52]
Cariprazine DMJYDVK Moderate Increased metabolism of Felbamate caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [48]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Felbamate and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [53]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Felbamate caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Lapatinib DM3BH1Y Moderate Increased metabolism of Felbamate caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
LY2835219 DM93VBZ Moderate Increased metabolism of Felbamate caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [55]
Exemestane DM9HPW3 Moderate Increased metabolism of Felbamate caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Felbamate caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
Tucatinib DMBESUA Moderate Increased metabolism of Felbamate caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [58]
Palbociclib DMD7L94 Moderate Increased metabolism of Felbamate caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Alpelisib DMEXMYK Moderate Increased metabolism of Felbamate caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Felbamate caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Felbamate caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Bosutinib DMTI8YE Moderate Increased metabolism of Felbamate caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Atorvastatin DMF28YC Moderate Increased metabolism of Felbamate caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [62]
Macitentan DMP79A1 Moderate Increased metabolism of Felbamate caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [63]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Felbamate caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [64]
PF-04449913 DMSB068 Moderate Increased metabolism of Felbamate caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [65]
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Felbamate when combined with Levomilnacipran. Chronic pain [MG30] [66]
Anisindione DM2C48U Moderate Decreased metabolism of Felbamate caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [67]
Drospirenone DM1A9W3 Major Increased metabolism of Felbamate caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [57]
Levonorgestrel DM1DP7T Major Increased metabolism of Felbamate caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [57]
Mestranol DMG3F94 Major Increased metabolism of Felbamate caused by Mestranol mediated induction of CYP450 enzyme. Contraceptive management [QA21] [68]
Norgestimate DMYP4XC Major Increased metabolism of Felbamate caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [68]
Levobupivacaine DM783CH Minor Increased metabolism of Felbamate caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [69]
Osilodrostat DMIJC9X Moderate Increased metabolism of Felbamate caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [70]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Felbamate caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [45]
Ivacaftor DMZC1HS Moderate Increased metabolism of Felbamate caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [71]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Felbamate caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [72]
Sertraline DM0FB1J Moderate Antagonize the effect of Felbamate when combined with Sertraline. Depression [6A70-6A7Z] [66]
Vilazodone DM4LECQ Moderate Antagonize the effect of Felbamate when combined with Vilazodone. Depression [6A70-6A7Z] [66]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Felbamate when combined with Vortioxetine. Depression [6A70-6A7Z] [66]
Milnacipran DMBFE74 Moderate Antagonize the effect of Felbamate when combined with Milnacipran. Depression [6A70-6A7Z] [66]
Escitalopram DMFK9HG Moderate Decreased metabolism of Felbamate caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [73]
Desvenlafaxine DMHD4PE Moderate Antagonize the effect of Felbamate when combined with Desvenlafaxine. Depression [6A70-6A7Z] [66]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Felbamate and Esketamine. Depression [6A70-6A7Z] [43]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Felbamate caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [74]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Felbamate caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [68]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Felbamate and Cannabidiol. Epileptic encephalopathy [8A62] [48]
Praziquantel DMOU1PK Moderate Increased metabolism of Felbamate caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [75]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Felbamate caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [76]
Tazemetostat DMWP1BH Moderate Increased metabolism of Felbamate caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [77]
Solifenacin DMG592Q Moderate Increased metabolism of Felbamate caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [78]
Mirabegron DMS1GYT Minor Increased metabolism of Felbamate caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [79]
Ripretinib DM958QB Moderate Increased metabolism of Felbamate caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [43]
Sunitinib DMCBJSR Moderate Increased metabolism of Felbamate caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [43]
Avapritinib DMK2GZX Moderate Increased metabolism of Felbamate caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [48]
Boceprevir DMBSHMF Moderate Increased metabolism of Felbamate caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [80]
Telaprevir DMMRV29 Moderate Increased metabolism of Felbamate caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [80]
Rifampin DMA8J1G Moderate Increased metabolism of Felbamate caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [45]
Rifapentine DMCHV4I Moderate Increased metabolism of Felbamate caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [45]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Felbamate and Brentuximab vedotin. Hodgkin lymphoma [2B30] [81]
MK-1439 DM215WE Moderate Increased metabolism of Felbamate caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Felbamate caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Fostemsavir DM50ILT Minor Increased metabolism of Felbamate caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Dolutegravir DMCZGRE Minor Increased metabolism of Felbamate caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Saquinavir DMG814N Moderate Increased metabolism of Felbamate caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Etravirine DMGV8QU Moderate Increased metabolism of Felbamate caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Felbamate caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Darunavir DMN3GCH Moderate Increased metabolism of Felbamate caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Atazanavir DMSYRBX Moderate Increased metabolism of Felbamate caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Felbamate and Mipomersen. Hyper-lipoproteinaemia [5C80] [87]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Felbamate and Teriflunomide. Hyper-lipoproteinaemia [5C80] [73]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Felbamate and BMS-201038. Hyper-lipoproteinaemia [5C80] [88]
Tolvaptan DMIWFRL Moderate Increased metabolism of Felbamate caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [48]
Suvorexant DM0E6S3 Moderate Increased metabolism of Felbamate caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [89]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Felbamate caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [90]
ITI-007 DMUQ1DO Major Increased metabolism of Felbamate caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [91]
Naloxegol DML0B41 Moderate Increased metabolism of Felbamate caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [92]
Pemigatinib DM819JF Moderate Increased metabolism of Felbamate caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [48]
Crizotinib DM4F29C Moderate Increased metabolism of Felbamate caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [93]
Brigatinib DM7W94S Moderate Increased metabolism of Felbamate caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [43]
Ceritinib DMB920Z Moderate Increased metabolism of Felbamate caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [94]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Felbamate caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [95]
Osimertinib DMRJLAT Moderate Increased metabolism of Felbamate caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [96]
Capmatinib DMYCXKL Moderate Increased metabolism of Felbamate caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [97]
Artemether DM48QOT Moderate Increased metabolism of Felbamate caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [43]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Felbamate when combined with Hydroxychloroquine. Malaria [1F40-1F45] [43]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Felbamate and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [98]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Felbamate and Idelalisib. Mature B-cell leukaemia [2A82] [99]
GDC-0199 DMH0QKA Moderate Increased metabolism of Felbamate caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [100]
IPI-145 DMWA24P Moderate Increased metabolism of Felbamate caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [101]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Felbamate caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [102]
Ibrutinib DMHZCPO Moderate Increased metabolism of Felbamate caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [103]
Vemurafenib DM62UG5 Moderate Increased metabolism of Felbamate caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [104]
LGX818 DMNQXV8 Moderate Increased metabolism of Felbamate caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [105]
Ethinyl estradiol DMODJ40 Major Increased metabolism of Felbamate caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [68]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Felbamate and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [106]
Ubrogepant DM749I3 Moderate Increased metabolism of Felbamate caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [107]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Felbamate and Lasmiditan. Migraine [8A80] [108]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Felbamate caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [64]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Felbamate and Flibanserin. Mood disorder [6A60-6E23] [109]
Panobinostat DM58WKG Moderate Increased metabolism of Felbamate caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [110]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Felbamate and Thalidomide. Multiple myeloma [2A83] [111]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Felbamate and Ocrelizumab. Multiple sclerosis [8A40] [112]
Nilotinib DM7HXWT Moderate Increased metabolism of Felbamate caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [113]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Felbamate caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [114]
Dasatinib DMJV2EK Moderate Increased metabolism of Felbamate caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [43]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Felbamate and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [115]
Rolapitant DM8XP26 Moderate Increased metabolism of Felbamate caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [116]
E-2007 DMJDYNQ Moderate Increased metabolism of Felbamate caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [48]
Entrectinib DMMPTLH Moderate Increased metabolism of Felbamate caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [117]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Felbamate caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [118]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Felbamate and Apraclonidine. Optic nerve disorder [9C40] [119]
Olaparib DM8QB1D Moderate Increased metabolism of Felbamate caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [43]
Hydrocodone DMQ2JO5 Moderate Increased metabolism of Felbamate caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [47]
Pimavanserin DMR7IVC Moderate Increased metabolism of Felbamate caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [120]
Macimorelin DMQYJIR Moderate Increased metabolism of Felbamate caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [121]
Lefamulin DME6G97 Moderate Increased metabolism of Felbamate caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [122]
Ergonovine DM0VEC1 Moderate Increased metabolism of Felbamate caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [43]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Felbamate caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [123]
Enzalutamide DMGL19D Moderate Increased metabolism of Felbamate caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [45]
Darolutamide DMV7YFT Moderate Increased metabolism of Felbamate caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [124]
Silodosin DMJSBT6 Moderate Increased metabolism of Felbamate caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [43]
Apremilast DMTWS9E Moderate Increased metabolism of Felbamate caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [125]
Everolimus DM8X2EH Moderate Increased metabolism of Felbamate caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [43]
Axitinib DMGVH6N Moderate Increased metabolism of Felbamate caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [126]
Temsirolimus DMS104F Moderate Increased metabolism of Felbamate caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [43]
Tofacitinib DMBS370 Moderate Increased metabolism of Felbamate caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [43]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Felbamate and Leflunomide. Rheumatoid arthritis [FA20] [73]
Aripiprazole DM3NUMH Moderate Increased metabolism of Felbamate caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [127]
Avanafil DM75CXN Moderate Increased metabolism of Felbamate caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [128]
LDE225 DMM9F25 Moderate Increased metabolism of Felbamate caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [129]
Larotrectinib DM26CQR Moderate Increased metabolism of Felbamate caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Docetaxel DMDI269 Moderate Increased metabolism of Felbamate caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [130]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Felbamate and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [48]
Armodafinil DMGB035 Moderate Increased metabolism of Felbamate caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [131]
Taxol DMUOT9V Moderate Increased metabolism of Felbamate caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [132]
Doxorubicin DMVP5YE Moderate Increased metabolism of Felbamate caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [48]
Fostamatinib DM6AUHV Moderate Increased metabolism of Felbamate caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [133]
Apixaban DM89JLN Moderate Increased metabolism of Felbamate caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [134]
Brilinta DMBR01X Moderate Increased metabolism of Felbamate caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [73]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Felbamate caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [135]
Saxagliptin DMGXENV Moderate Increased metabolism of Felbamate caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [136]
Linagliptin DMWFJTR Moderate Increased metabolism of Felbamate caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [137]
Elagolix DMB2C0E Moderate Increased metabolism of Felbamate caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [138]
Ganciclovir DM1MBYQ Moderate Increased risk of nephrotoxicity by the combination of Felbamate and Ganciclovir. Virus infection [1A24-1D9Z] [43]
Valganciclovir DMS2IUH Moderate Increased risk of nephrotoxicity by the combination of Felbamate and Valganciclovir. Virus infection [1A24-1D9Z] [43]
⏷ Show the Full List of 147 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Felbamate 400 mg tablet 400 mg Oral Tablet Oral
Felbamate 600 mg tablet 600 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5473).
2 Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs. 2008;10(4):217-54.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
10 Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2008;81(3):259-65.
11 Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85-110.
12 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
13 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
24 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
25 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
26 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
27 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
28 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
30 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
31 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
32 Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
33 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
34 Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
35 Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
36 The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
37 Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
38 Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
39 Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
40 Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
41 Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
42 Gidal BE, Zupanc ML "Potential pharmacokinetic interaction between felbamate and phenobarbital." Ann Pharmacother 28 (1994): 455-8. [PMID: 8038465]
43 Cerner Multum, Inc. "Australian Product Information.".
44 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
45 Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH "Pharmacokinetic interactions with felbamate.In vitro-in vivo correlation." Clin Pharmacokinet 33 (1997): 214-24. [PMID: 9314612]
46 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
47 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
48 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
49 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
50 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
51 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
52 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
53 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
54 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
55 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
56 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
57 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
58 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
59 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
61 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
63 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
64 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
65 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
66 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
67 Glue P, Banfield CR, Colucci RD, Perhach JL "Warfarin-felbamate interaction." Ann Pharmacother 28 (1994): 1412-3. [PMID: 7696739]
68 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
69 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
70 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
71 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
72 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
73 Canadian Pharmacists Association.
74 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
75 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
76 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
77 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
78 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
79 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
80 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
81 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
82 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
83 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
84 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
85 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
86 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
87 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
88 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
89 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
90 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
91 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
92 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
93 Cerner Multum, Inc. "Canadian Product Information.".
94 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
95 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
96 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
97 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
98 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
99 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
100 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
101 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
102 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
103 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
104 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
105 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
106 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
107 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
108 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
109 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
110 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
111 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
112 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
113 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
114 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
115 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
116 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
117 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
118 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
119 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
120 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
121 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
122 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
123 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
124 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
125 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
126 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
127 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
128 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
129 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
130 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
131 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
132 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
133 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
134 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
135 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
136 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
137 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
138 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.